Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress... The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac®, LBH589) was developed by Novartis Pharmaceuticals and has been recently approved by the US Food and Drug Administraion (FDA) as a drug to treat multiple myeloma. It is under clinical investigation for a range of haematological and solid tumors worldwide in both oral and intravenous formulations. Panobinostat inhibits tumor cell growth by interacting with acetylation of histones and non-histone proteins as well as various apoptotic, autophagy-mediated targets and various tumorogenesis pathways involved in development of tumors. The optimal combination regimen for pancreatic cancer remains to be fully elucidated with various combination regimens, and should be investigated in clinical trials. This article summarizes the current preclinical and clinical status of panobinostat in pancreatic cancer. Preclinical data suggests that panobinostat has potential inhibitory activity in pancreatic cancer cells by targeting various pathways and factors involved in the development of cancer. Herein, we reviewed the status of mono and combination therapy and the rationale behind the combination therapy undergoing trials, as well as possible future prospective use in the treatment of pancreatic cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/panobinostat-as-pan-deacetylase-inhibitor-for-the-treatment-of-uC9e0kn6ab
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0023-1
Publisher site
See Article on Publisher Site

Abstract

The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac®, LBH589) was developed by Novartis Pharmaceuticals and has been recently approved by the US Food and Drug Administraion (FDA) as a drug to treat multiple myeloma. It is under clinical investigation for a range of haematological and solid tumors worldwide in both oral and intravenous formulations. Panobinostat inhibits tumor cell growth by interacting with acetylation of histones and non-histone proteins as well as various apoptotic, autophagy-mediated targets and various tumorogenesis pathways involved in development of tumors. The optimal combination regimen for pancreatic cancer remains to be fully elucidated with various combination regimens, and should be investigated in clinical trials. This article summarizes the current preclinical and clinical status of panobinostat in pancreatic cancer. Preclinical data suggests that panobinostat has potential inhibitory activity in pancreatic cancer cells by targeting various pathways and factors involved in the development of cancer. Herein, we reviewed the status of mono and combination therapy and the rationale behind the combination therapy undergoing trials, as well as possible future prospective use in the treatment of pancreatic cancer.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 10, 2016

References

  • Epidemiology of pancreatic cancer: an overview
    Raimondi, S; Maisonneuve, P; Lowenfels, AB
  • Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
    Caldas, C; Hahn, SA; da Costa, LT
  • Genetic and epigenetic alterations in pancreatic carcinogenesis
    Delper, Y; Hanoun, N; Lulka, H
  • Anticancer activities of histone deacetylase inhibitors
    Bolden, JE; Peart, MJ; Johnstone, RW
  • Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
    Gryder, BE; Sodji, QH; Oyelere, AK
  • A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity
    Rajak, H; Singh, A; Raghuwanshi, K
  • A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Giles, F; Fischer, T; Cortes, J
  • A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors
    Jones, SF; Bendell, JC; Infante, JR
  • Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
    Rasmussen, TA; Sogaard, OS; Brinkmann, C
  • Both class I and class II histone deacetylases are required for proliferation and survival of human pancreatic cancer cells (abstract no 1830)
    Wang, G; He, J; Taub, JW
  • Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma
    Schneider, G; Kramer, OH; Schmid, RM
  • High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas
    Ouaissi, M; Sielezneff, I; Silvestre, R
  • Silencing of the transforming growth factor-beta (TGFbeta) receptor II by Kruppel-like factor 14 underscores the importance of a negative feedback mechanism in TGFbeta signaling
    Truty, MJ; Lomberk, G; Fernandez-Zapico, ME
  • Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors
    Rikiishi, H
  • HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
    Fritsche, P; Seidler, B; Schuler, S
  • HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
    Schuler, S; Fritsche, P; Diersch, S
  • Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
    Goggins, M; Shekher, M; Turnacioglu, K
  • The emerging role of the TGF-beta tumor suppressor pathway in pancreatic cancer
    Birnbaum, DJ; Mamessier, E; Birnbaum, D
  • TGF-beta signaling and epithelial–mesenchymal transition in cancer progression
    Katsuno, Y; Lamouille, S; Derynck, R
  • The cell-cell adhesion molecule E-cadherin
    Roy, F; Berx, G
  • Genome regulation by polycomb and trithorax proteins
    Schuettengruber, B; Chourrout, D; Vervoort, M
  • Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2
    Ougolkov, AV; Bilim, VN; Billadeau, DD
  • MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival
    Dillhoff, M; Liu, J; Frankel, W
  • MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance
    Moriyama, T; Ohuchida, K; Mizumoto, K
  • Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation
    Du, Y; Liu, M; Gao, J
  • Apoptosis and the target genes of microRNA-21
    Buscaglia, LE; Li, Y
  • Histone deacetylase inhibitors current status and overview of recent clinical trials
    Ma, X; Ezzeldin, HH; Diasio, RB
  • Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo
    Chien, W; Lee, DH; Zheng, Y
  • Targeting tumor angiogenesis with histone deacetylase inhibitors
    Ellis, L; Hammers, H; Pili, R
  • Myeloma therapy
    Hideshima, T
  • Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
    Qian, DZ; Kato, Y; Shabbeer, S
  • Histone deacetylase inhibitors: multifunctional anticancer agents
    Liu, T; Kuljaca, S; Tee, A
  • Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7
    Wang, S; Li, X; Parra, M
  • Histone deacetylase inhibitors induced caspase independent apoptosis in human pancreatic adenocarcinoma cell lines
    Garcia-Morales, P; Gomez-Martinez, A; Carrato, A
  • Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Mitsiades, N; Mitsiades, CS; Richardson, PG
  • C-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589
    Kauh, J; Fan, S; Xia, M
  • Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways
    Natoni, F; Diolordi, L; Santoni, C
  • Targeting apoptosis pathways in pancreatic cancer
    Arlt, A; Muerkoster, SS; Schafer, H
  • Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro-and antiapoptotic genes in pancreatic adenocarcinoma cells
    Moore, PS; Barbi, S; Donadelli, M
  • Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
    Donadelli, M; Costanzo, C; Beghelli, S
  • Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
    Newbold, A; Lindemann, RK; Cluse, LA
  • Histone deacetylase inhibitors: potential in cancer therapy
    Marks, P; Xu, WS
  • HDAC modulation and cell death in the clinic
    Dell’Aversana, C; Lepore, I; Altucci, L
  • Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
    Ungerstedt, J; Sowa, Y; Xu, WS
  • In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Ungerstedt, J; Du, Y; Zhang, H
  • Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis
    Wang, B; Wang, XB; Chen, LY
  • Histone deacetylase inhibitors: signaling towards p21 cip1/waf1
    Ocker, M; Schneider-Stock, R
  • SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines
    Ryu, JK; Lee, WJ; Lee, KH
  • Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells
    Sung, V; Richard, N; Brady, H
  • Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells
    Qiao, Z; Ren, S; Li, W
  • Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer
    Wang, G; He, J; Zhao, J
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
    Arumugam, T; Ramachandran, V; Fournier, KF
  • Epithelial–mesenchymal transition in pancreatic carcinoma
    Maier, HJ; Wirth, T; Beug, H
  • Epithelial–mesenchymal transition in cancer development and its clinical significance
    Iwatsuki, M; Mimori, K; Yokobori, T
  • Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer
    Aghdassi, A; Sendler, M; Guenther, A
  • Epithelial-mesenchymal transition in pancreatic cancer: is it a clinically significant factor?
    Jiang, JH; Liu, C; Cheng, H
  • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells
    Kumagai, T; Wakimoto, N; Yin, D
  • The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer
    Shapiro, GI; Frank, R; Dandamudi, UB
  • Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors
    Konsoula, Z; Cao, H; Velena, A
  • Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors
    Morita, S; Oizumi, S; Minami, H
  • A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Fukutomi, A; Hatake, K; Matsui, K
  • Panobinostat: first global approval
    Garnock-Jones, KP
  • Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
    Hamberg, P; Woo, MM; Chen, LC
  • A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Slingerland, M; Hess, D; Clive, S
  • A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer
    Feld, R; Woo, MM; Leighl, N
  • A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sharma, S; Witteveen, PO; Lolkema, MP
  • Rapid recovery from panobinostat (LBH589) induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
    Giver, CR; Jaye, DL; Waller, EK
  • Clinical toxicities of histone deacetylase inhibitors
    Subramanian, S; Bates, SE; Wright, JJ
  • Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)
    Zhang, L; Lebwohl, D; Masson, E
  • HDACI-induced thrombocytopenia is caused by its unexpected target
    Kitamura, T; Inoue, D
  • Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide
    Bishton, MJ; Gardiner, EE; Harrison, SJ
  • Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges
    Atadja, P
  • Nonhistone protein acetylation as cancer therapy targets
    Singh, BN; Zhang, G; Hwa, YL
  • Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs
    Kim, HJ; Bae, SC
  • Inhibition of Plk1 and cyclin B1 expression results in panobinostat-induced G2 delay and mitotic defects
    Prystowsky, M; Feeney, K; Kawachi, N
  • Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors
    Bali, P; Pranpat, M; Bradner, J
  • Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor dependent human lung cancer cells
    Edwards, A; Li, J; Atadja, P
  • DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions
    Gandesiri, M; Chakilam, S; Ivanovska, J
  • Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade
    Reddy, RM; Yeow, WS; Chua, A
  • Modulation of TRAIL-induced apoptosis by HDAC inhibitors
    Fulda, S
  • Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment
    Meng, X; Brachova, P; Yang, S
  • The phosphatidylinositol 3-kinases (PI3 K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways
    Bodo, J; Zhao, X; Sharma, A
  • Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
    Yu, C; Friday, BB; Lai, JP
  • The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
    Lisiero, DN; Soto, H; Everson, RG
  • Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
    Cao, K; Wang, G; Li, W
  • HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)
    Mehdi, O; Francoise, S; Sofia, CL
  • Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
    Haefner, M; Bluethner, T; Niederhagen, M
  • Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy
    Wang, H; Cao, Q; Dudek, AZ
  • Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
    Venkannagari, S; Fiskus, W; Peth, K
  • Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
    Wang, G; Niu, X; Zhang, W
  • Ron knockdown and ron monoclonal antibody IMCRON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)
    Zou, Y; Howell, GM; Humphrey, LE
  • Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors
    Rikiishi, H